NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.49 -0.04 (-1.58 %)
(As of 08/21/2018 09:28 AM ET)
Previous Close$2.53
Today's Range$2.4450 - $2.56
52-Week Range$2.33 - $5.19
Volume492,886 shs
Average Volume910,629 shs
Market Capitalization$350.62 million
P/E Ratio-4.02
Dividend YieldN/A
Beta0.95
Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio35.95
Quick Ratio35.95

Price-To-Earnings

Trailing P/E Ratio-4.02
Forward P/E Ratio-4.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$15 million
Price / Sales23.01
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.06

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-25.26%
Return on Assets-24.41%

Miscellaneous

Employees88
Outstanding Shares138,590,000
Market Cap$350.62 million

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

6 equities research analysts have issued 1-year target prices for Achillion Pharmaceuticals' stock. Their predictions range from $3.50 to $6.50. On average, they anticipate Achillion Pharmaceuticals' share price to reach $4.80 in the next twelve months. This suggests a possible upside of 92.8% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.

What is the consensus analysts' recommendation for Achillion Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 53)
  • Ms. Mary Kay Fenton, Exec. VP, CFO & Treasurer (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)
  • Glenn Schulman, Exec. Director of Investor Relations
  • Ms. Ky Nam-Wortman, Head of HR and VP

Has Achillion Pharmaceuticals been receiving favorable news coverage?

News headlines about ACHN stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news impact score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Achillion Pharmaceuticals.

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include RTW Investments LP (9.77%), BlackRock Inc. (8.58%), Dimensional Fund Advisors LP (4.98%), Baker BROS. Advisors LP (1.40%), DAFNA Capital Management LLC (0.68%) and Renaissance Technologies LLC (0.53%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which major investors are selling Achillion Pharmaceuticals stock?

ACHN stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Renaissance Technologies LLC, Schwab Charles Investment Management Inc., Alps Advisors Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Achillion Pharmaceuticals.

Which major investors are buying Achillion Pharmaceuticals stock?

ACHN stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, GSA Capital Partners LLP, BlackRock Inc., United Services Automobile Association, Spark Investment Management LLC, DAFNA Capital Management LLC, BlueMountain Capital Management LLC and Bank of America Corp DE. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $2.49.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $350.62 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  409 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel